Clinical Trials Browser

Phase 2/3 × OTHER × Silymarin × Clear all

NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Phase 2/3 Unknown

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

NCT01829178 2015-05-13

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

Phase 2/3 Completed

Gastrointestinal

Gastrointestinal Neoplasms